More insurance plans than ever are offering Taltz as the Preferred IL-17A antagonist across Commercial and Part D.
Learn more
Taltz is indicated for adults with active psoriatic arthritis (PsA), for adults with active ankylosing spondylitis (AS), and for adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. Taltz is also indicated for patients aged 6 years or older with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.
Powerful and consistent results within the spectrum of SpA1-14
For patients with PsA
SPIRIT-P1 (biologic-naive) trial results
Taltz
|
Placebo
| |
|---|---|---|
|
ACR50 % achieving response at week 24
Click here for more, including SPIRIT-P2 results See SPIRIT-P1 and SPIRIT-P2 trial designs | Taltz40%* | Placebo15%
Click here for more, including SPIRIT-P2 results See SPIRIT-P1 and SPIRIT-P2 trial designs |
| ACR50 % achieving response at week 156 NRI Click here for more | Taltz52% | Placebo Click here for more |
*P≤.001 vs placebo.
Primary endpoint=ACR20 response at week 24.
The uncontrolled extension period of the study (weeks 24-156) has limitations (eg, no placebo comparison; patients remaining in the extension phase may be those more responsive to treatment).
See SPIRIT-P1 and SPIRIT-P2 trial designsSPIRIT-H2H (biologic-naive) trial results
Taltz
|
Humira
| |
|---|---|---|
| ACR50 + PASI 100 % achieving response at week 24 | Taltz36%§ | Humira28% |
| ACR50 % achieving response at week 24 | Taltz51% | Humira47% |
| ACR70 % achieving response at week 24 | Taltz32% | Humira26% |
§P<.05 vs Humira at week 24.
All patients had BSA ≥3%; patients with BSA ≥10%, PASI ≥12, sPGA ≥3 followed the dosing for moderate-to-severe PsO.9
Primary endpoint=simultaneous achievement of ACR50 and PASI 100 at week 24.9
Major secondary objective met: demonstrated noninferiority of Taltz vs Humira on ACR50 response at 24 weeks (95% CI [-4.3%, 12.1%]) for noninferiority with -12.0% margin.
ACR70 at week 24 was prespecified but not type-l error-controlled; therefore, results cannot be regarded as statistically significant.
See SPIRIT-H2H trial designFor patients with AS
COAST-V (biologic-naive) trial results
Taltz
|
Placebo
| |
|---|---|---|
| ASAS40 % achieving response at week 16 | Taltz48%† | Placebo18% |
| ASAS40 % achieving response at week 52 Click here for more, including COAST-W results | Taltz53% | Placebo Click here for more, including COAST-W results |
†P≤.0001 vs placebo.
Primary endpoint=ASAS40 at week 16.
The extended treatment period of the study (weeks 16-52) has limitations (eg, no placebo comparison, patients remaining in the extension phase may be those more responsive to treatment).
See COAST-V and COAST-W trial designsFor patients with nr-axSpA
COAST-X (biologic-naive) trial results
Taltz
|
Placebo
| |
|---|---|---|
| ASAS40 % achieving response at week 16 | Taltz35%* | Placebo19% |
| ASAS40 % achieving response at week 52 Click here for more | Taltz30%† | Placebo13%
Click here for more |
*P<.01 vs placebo at week 16.
†P=0.0045 vs placebo at week 52.
Primary endpoint=ASAS40 at week 52.
Starting at week 16 and up to week 44, changes could b made to non-biologic background therapy and/or patients could be transitioned to open-label Taltz 80mg every 2 weeks at the investigators' discretion. Patients who switched to Taltz 80mg every 2 weeks, were missing week 16 or week 52 data, or discontinued double-blind treatment were considered nonresponders. Taltz 80mg every 2 weeks is not an approved dose for nr-axSpA.
See COAST-X trial designSELECT IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.